GlassScriptPhysician profile
Jay G Robinson
NPI 1083610083
$1,797.06
in general payments reported to CMS, 2019-2025
37 companies · $31.04 in 2025
The $31.04 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $391 · 2021: $52.49 · 2022: $195 · 2023: $138 · 2024: $107 · 2025: $31.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $267.20 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $239.40 | 2019-2020 | |
| Abbvie INC. | $214.38 | 2019-2025 | Botox, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $87.32 | 2020 | |
| Tersera Therapeutics LLC | $80.34 | 2019 | |
| Pfizer INC. | $76.34 | 2019-2024 | |
| Allergan, INC. | $75.70 | 2019-2020 | |
| Emd Serono, INC. | $74.57 | 2019-2020 | |
| Amgen INC. | $51.88 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $41.31 | 2021 | |
| Acadia Pharmaceuticals INC | $38.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.75 | 2019 | |
| Lundbeck LLC | $34.47 | 2019-2020 | |
| Harmony Biosciences LLC | $34.06 | 2022 | |
| Biogen, INC. | $32.78 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microtransponder, INC. | $28.17 | 2024 | |
| Adamas Pharmaceuticals, INC. | $28.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.34 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $26.74 | 2022 | |
| Tanabe Pharma America, INC. | $23.29 | 2020 | |
| Grt US Holding, INC. | $23.20 | 2022 | |
| Sk Life Science, INC. | $21.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.40 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.13 | 2020 | |
| Genzyme Corporation | $17.68 | 2019 | |
| Ge Healthcare | $17.52 | 2019 | |
| Neurocrine Biosciences, INC. | $17.25 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.16 | 2023 | Acthar |
| Aprecia Pharmaceuticals, LLC | $17.01 | 2020 | |
| Genentech USA, INC. | $16.31 | 2023 | Ocrevus, Enspryng |
| Eisai INC. | $15.88 | 2019 | |
| Banner Life Sciences, LLC | $15.63 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.61 | 2019 | |
| Sumitomo Pharma America, INC. | $13.46 | 2024 | Aptiom |
| Mdd US Operations, LLC | $12.59 | 2019 | |
| Ucb, INC. | $12.24 | 2019 | |
| Boston Scientific Corporation | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.